Sentry Investments Corp. Raises Holdings in Pfizer Inc. (PFE)

Sentry Investments Corp. raised its stake in Pfizer Inc. (NYSE:PFE) by 375.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,735,100 shares of the biopharmaceutical company’s stock after acquiring an additional 2,160,400 shares during the period. Sentry Investments Corp. owned 0.16% of Pfizer worth $91,872,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Shine Investment Advisory Services Inc. acquired a new position in Pfizer in the second quarter valued at approximately $102,000. D. Scott Neal Inc. boosted its stake in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC acquired a new position in Pfizer in the first quarter valued at approximately $121,000. Herndon Capital Management LLC acquired a new position in Pfizer in the second quarter valued at approximately $120,000. Finally, Lipe & Dalton boosted its stake in Pfizer by 6.9% in the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after acquiring an additional 300 shares during the period. Institutional investors own 69.89% of the company’s stock.

In related news, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the sale, the insider now owns 117,432 shares of the company’s stock, valued at $4,145,349.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the sale, the insider now directly owns 145,649 shares in the company, valued at approximately $5,097,715. The disclosure for this sale can be found here. In the last three months, insiders have sold 60,280 shares of company stock worth $2,118,988. 0.06% of the stock is owned by corporate insiders.

PFE has been the subject of a number of research reports. Cowen set a $43.00 target price on Pfizer and gave the company a “buy” rating in a research note on Monday, August 14th. BMO Capital Markets set a $37.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, October 10th. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Tuesday, October 3rd. Finally, Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, September 19th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $38.77.

Shares of Pfizer Inc. (NYSE:PFE) traded down $0.43 during trading hours on Wednesday, reaching $35.63. The company had a trading volume of 22,320,600 shares, compared to its average volume of 19,989,418. Pfizer Inc. has a 1 year low of $30.51 and a 1 year high of $36.78. The company has a market capitalization of $211,960.00, a PE ratio of 14.42, a price-to-earnings-growth ratio of 2.54 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter in the previous year, the company earned $0.61 earnings per share. The firm’s quarterly revenue was up .9% compared to the same quarter last year. equities analysts predict that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.59%. Pfizer’s payout ratio is 78.53%.

TRADEMARK VIOLATION NOTICE: This article was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.com-unik.info/2017/12/06/sentry-investments-corp-raises-holdings-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit